Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Next Previous
Trial Profile

Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Genentech; Roche

    • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 7 Nov 2018 to 10 Dec 2020.
    • 27 May 2017 This trial has been completed in Slovakia.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top